Table 1. Pharmcokinetic parameters for PLD and NonL-doxo.
| Matrix | Pharmacokinetic Parameters | |||||
| PEGylated liposomal-doxorubicin | Non-liposomal doxorubicin | |||||
| AUC0-(ng/mL·h) | tmax(h) | Cmax(ng/mL) | AUC0-∞(ng/mL·h) | tmax(h) | Cmax(ng/mL) | |
| Plasma | 2,257,480 | 3 | 197,020 | 1,545 | 0.083 | 831 |
| Brain Tumor | 229,716 | 3 | 2,181 | 12,134 | 6 | 570 |
| Normal Brain | 13,742 | 3 | 854 | 326 | 1 | 92 |
| Peri-Tumoral Brain | 23,972 | 3 | 725 | 283 | 3 | 32 |
Noncompartmental pharmacokinetic parameters following administration of PEGylated liposomal-doxorubicin and non-liposomal doxorubicin at 6 mg/kg IV ×1 in female athymic nude (nu/nu) mice bearing intracranial MDA-MB-231-BR human triple-negative breast cancer xenografts.